中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 5
May  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(5): 1201-1204

Current status of research on hepatic encephalopathy after transjugular intrahepatic portosystemic shunt

DOI: 10.3969/j.issn.1001-5256.2021.05.047
  • 1.

    Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China

  • 2.

    Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China

  • Received Date: 2020-10-30
  • Accepted Date: 2020-12-15
  • Published Date: 2021-05-20
    Abstract
  • Hepatic encephalopathy (HE) is a common complication after transjugular intrahepatic portosystemic shunt (TIPS), and there are still no systematic strategies for prevention and treatment at present. Based on recent studies in China and foreign countries, this article analyzes and summarizes the risk factors for HE after TIPS and the advances in treatment and prevention. It is pointed out that early diagnosis and prevention of covert HE should be emphasized in further research, and it is important to standardize the prevention strategies for HE after TIPS.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol, 2018, 34(10): 2076-2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007.

    中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南[J]. 临床肝胆病杂志, 2018, 34(10): 2076-2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007.
    [2]
    PATIDAR KR, BAJAJ JS. Covert and overt hepatic encephalopathy: Diagnosis and management[J]. Clin Gastroenterol Hepatol, 2015, 13(12): 2048-2061. DOI: 10.1016/j.cgh.2015.06.039.
    [3]
    LI Y, HE X, PANG H. A model to predict early hepatic encephalopathy in patients undergoing transjugular intrahepatic portosystemic shunt[J]. Turk J Gastroenterol, 2019, 30(8): 702-707. DOI: 10.5152/tjg.2019.18485.
    [4]
    BETTINGER D, SCHULTHEISS M, BOETTLER T, et al. Procedural and shunt-related complications and mortality of the transjugular intrahepatic portosystemic shunt (TIPSS)[J]. Aliment Pharmacol Ther, 2016, 44(10): 1051-1061. DOI: 10.1111/apt.13809.
    [5]
    PERARNAU JM, LE GOUGE A, NICOLAS C, et al. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: A randomized controlled trial[J]. J Hepatol, 2014, 60(5): 962-968. DOI: 10.1016/j.jhep.2014.01.015.
    [6]
    BUREAU C, GARCIA-PAGAN JC, OTAL P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: Results of a randomized study[J]. Gastroenterology, 2004, 126(2): 469-475. DOI: 10.1053/j.gastro.2003.11.016.
    [7]
    VILSTRUP H, AMODIO P, BAJAJ J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver[J]. Hepatology, 2014, 60(2): 715-735. DOI: 10.1002/hep.27210.
    [8]
    NARDELLI S, GIOIA S, PASQUALE C, et al. Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Am J Gastroenterol, 2016, 111(4): 523-528. DOI: 10.1038/ajg.2016.29.
    [9]
    SAID VJ, GARCIA-TRUJILLO E. Beyond lactulose: Treatment options for hepatic encephalopathy[J]. Gastroenterol Nurs, 2019, 42(3): 277-285. DOI: 10.1097/SGA.0000000000000376.
    [10]
    LUO M, LI L, YANG EN, et al. Correlation between interleukin-6 and ammonia in patients with overt hepatic encephalopathy due to cirrhosis[J]. Clin Res Hepatol Gastroenterol, 2013, 37(4): 384-390. DOI: 10.1016/j.clinre.2012.08.007.
    [11]
    SURAWEERA D, SUNDARAM V, SAAB S. Evaluation and management of hepatic encephalopathy: Current status and future directions[J]. Gut Liver, 2016, 10(4): 509-519. DOI: 10.5009/gnl15419.
    [12]
    SFARTI C, CIOBICA A, BALMUS IM, et al. Systemic oxidative stress markers in cirrhotic patients with hepatic encephalopathy: Possible connections with systemic ammoniemia[J]. Medicina (Kaunas), 2020, 56(4): 196. DOI: 10.3390/medicina56040196.
    [13]
    JI XT, HE YH, QI YY, et al. Mechanism of action of intestinal flora in hepatic encephalopathy[J]. J Clin Hepatol, 2020, 36(3): 690-692. DOI: 10.3969/j.issn.1001-5256.2020.03.049.

    姬晓彤, 贺韵涵, 戚莹媛, 等. 肠道菌群在肝性脑病中的作用机制[J]. 临床肝胆病杂志, 2020, 36(3): 690-692. DOI: 10.3969/j.issn.1001-5256.2020.03.049.
    [14]
    RIDOLA L, RIGGIO O, GIOIA S, et al. Clinical management of type C hepatic encephalopathy[J]. United European Gastroenterol J, 2020, 8(5): 536-543. DOI: 10.1177/2050640620909675.
    [15]
    ZIVONY AS, CHEN L, KAUFMAN J, et al. The degree in reduction of portal-systemic gradient during tips and not final post-tips portal pressure gradient is predictive of the development of hepatic encephalopathy[J]. Gastroenterology, 2014, 146(5): S-932.
    [16]
    BAI M, QI X, YANG Z, et al. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: A systematic review[J]. J Gastroenterol Hepatol, 2011, 26(6): 943-951. DOI: 10.1111/j.1440-1746.2011.06663.x.
    [17]
    YIN X, ZHANG F, XIAO J, et al. Diabetes mellitus increases the risk of hepatic encephalopathy after a transjugular intrahepatic portosystemic shunt in cirrhotic patients[J]. Eur J Gastroenterol Hepatol, 2019, 31(10): 1264-1269. DOI: 10.1097/MEG.0000000000001452.
    [18]
    NARDELLI S, LATTANZI B, TORRISI S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement[J]. Clin Gastroenterol Hepatol, 2017, 15(6): 934-936. DOI: 10.1016/j.cgh.2016.10.028.
    [19]
    ROWLEY MW, CHOI M, CHEN S, et al. Refractory hepatic encephalopathy after elective transjugular intrahepatic portosystemic shunt: Risk factors and outcomes with revision[J]. Cardiovasc Intervent Radiol, 2018, 41(11): 1765-1772. DOI: 10.1007/s00270-018-1992-2.
    [20]
    FONIO P, DISCALZI A, CALANDRI M, et al. Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification[J]. Radiol Med, 2017, 122(9): 713-721. DOI: 10.1007/s11547-017-0770-6.
    [21]
    CASADABAN LC, PARVINIAN A, MINOCHA J, et al. Clearing the confusion over hepatic encephalopathy after TIPS creation: Incidence, prognostic factors, and clinical outcomes[J]. Dig Dis Sci, 2015, 60(4): 1059-1066. DOI: 10.1007/s10620-014-3391-0.
    [22]
    ROUTHU M, SAFKA V, ROUTHU SK, et al. Observational cohort study of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS)[J]. Ann Hepatol, 2017, 16(1): 140-148. DOI: 10.5604/16652681.1226932.
    [23]
    LEWIS DS, LEE TH, KONANUR M, et al. Proton pump inhibitor use is associated with an increased frequency of new or worsening hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation[J]. J Vasc Interv Radiol, 2019, 30(2): 163-169. DOI: 10.1016/j.jvir.2018.10.015.
    [24]
    STURM L, BETTINGER D, GIESLER M, et al. Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS)[J]. United European Gastroenterol J, 2018, 6(9): 1380-1390. DOI: 10.1177/2050640618795928.
    [25]
    PEREIRA K, CARRION AF, SALSAMENDI J, et al. Endovascular management of refractory hepatic encephalopathy complication of transjugular intrahepatic portosystemic shunt (TIPS): Comprehensive review and clinical practice algorithm[J]. Cardiovasc Intervent Radiol, 2016, 39(2): 170-182. DOI: 10.1007/s00270-015-1197-x.
    [26]
    LUO L, FU S, ZHANG Y, et al. Early diet intervention to reduce the incidence of hepatic encephalopathy in cirrhosis patients: Post-transjugular intrahepatic portosystemic shunt (TIPS) findings[J]. Asia Pac J Clin Nutr, 2016, 25(3): 497-503. DOI: 10.6133/apjcn.092015.14.
    [27]
    SHARMA BC, SHARMA P, LUNIA MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy[J]. Am J Gastroenterol, 2013, 108(9): 1458-1463. DOI: 10.1038/ajg.2013.219.
    [28]
    BAI M, YANG Z, QI X, et al. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials[J]. J Gastroenterol Hepatol, 2013, 28(5): 783-792. DOI: 10.1111/jgh.12142.
    [29]
    PEREIRA K, CARRION AF, MARTIN P, et al. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy[J]. Liver Int, 2015, 35(12): 2487-2494. DOI: 10.1111/liv.12956.
    [30]
    ZHAO YJ, HAN GH, YIN ZX, et al. Clinical analysis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS)[J]. Contemporary Medicine, 2010, 16(11): 139-141. DOI: 10.3969/j.issn.1009-4393.2010.11.004.

    赵延军, 韩国宏, 殷占新, 等. 经颈静脉肝内门体分流(TIPS)术后并发肝性脑病的临床分析[J]. 当代医学, 2010, 16(11): 139-141. DOI: 10.3969/j.issn.1009-4393.2010.11.004.
    [31]
    WANG Q, LV Y, BAI M, et al. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding[J]. J Hepatol, 2017, 67(3): 508-516. DOI: 10.1016/j.jhep.2017.05.006.
    [32]
    SCHEPIS F, VIZZUTTI F, GARCIA-TSAO G, et al. Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2018, 16(7): 1153-1162. e7. DOI: 10.1016/j.cgh.2018.01.029.
    [33]
    LUO SH, CHU JG, HUANG H, et al. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy[J]. World J Gastroenterol, 2019, 25(9): 1088-1099. DOI: 10.3748/wjg.v25.i9.1088.
    [34]
    CHUNG HH, RAZAVI MK, SZE DY, et al. Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: What is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications?[J]. J Gastroenterol Hepatol, 2008, 23(1): 95-101. DOI: 10.1111/j.1440-1746.2006.04697.x.
    [35]
    SHI Y, TIAN X, HU J, et al. Efficacy of transjugular intrahepatic portosystemic shunt with adjunctive embolotherapy with cyanoacrylate for esophageal variceal bleeding[J]. Dig Dis Sci, 2014, 59(9): 2325-2332. DOI: 10.1007/s10620-014-3150-2.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (573) PDF downloads(56) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return